After achieving HIV-1 RNA < 50 copies/mL on two consecutive occasions between weeks 12 and 24 after baseline , 120 patients ( baseline : median HIV-1 RNA 5.19 log10 copies/mL ; median CD4 count 180 cells/L ) were randomized to receive abacavir/lamivudine/zidovudine ( ABC/3TC/ZDV ) ( n = 61 ) or to continue the PI-based ART ( n = 59 ) .